問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Others-Department of Medical Imaging

Division of Radiology

Division of Nuclear Medicine

Division of Neurology

Division of Hematology & Oncology

更新時間:2023-09-19

陳雅芳CHEN, YA-FANG
  • Principal Investigator
  • Clinical Trial Experience (year) 7 years 9 個月

篩選

List

64Cases

2020-12-01 - 2022-11-30

Phase III

Completed
A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
  • Condition/Disease

    RELAPSING MULTIPLE SCLEROSIS

  • Test Drug

    Fenebrutinib Aubagio

Participate Sites
3Sites

Recruiting3Sites

2021-02-01 - 2027-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2020-10-01 - 2024-12-31

Phase III

Completed
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple Sclerosis
  • Condition/Disease

    Relapsing Multiple Sclerosis

  • Test Drug

    SAR442168 60mg or Teriflunomide 14mg or placebo

Participate Sites
6Sites

Recruiting6Sites

2012-04-01 - 2017-03-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2021-09-01 - 2025-03-31

Phase I/II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-01-31 - 2028-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-02-19 - 2025-12-31

Phase I

Completed
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and CLL
  • Condition/Disease

    Non-Hodgkin Lymphoma/Chronic lymphoid leukemia

  • Test Drug

    JNJ-75348780

Participate Sites
5Sites

Not yet recruiting2Sites

Terminated3Sites

2023-12-15 - 2030-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting5Sites

Recruiting3Sites

2018-02-01 - 2024-12-31

Phase II

Active
A Randomized, Double Blinded, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia
  • Condition/Disease

    Parkinson′s disease dementia

  • Test Drug

    ceftriaxone

Participate Sites
11Sites

Recruiting5Sites

Terminated5Sites